In First Personalized T-cell Trial, Long-Term Remissions for Chronic Leukemia

Share this content:
An experimental therapy for chronic lymphocytic leukemia that uses a patient's own T cells may cure patients and prolong survival.
An experimental therapy for chronic lymphocytic leukemia that uses a patient's own T cells may cure patients and prolong survival.

An experimental therapy for chronic lymphocytic leukemia that uses a patient's own T cells (an approach known as CTL019) may cure some patients and prolong survival in others, researchers report. The study was published in Science Translational Medicine.

The current study is a follow-up of 14 patients given the CTL019 treatment in 2010. Eight of the 14 patients responded to the treatment.

Four achieved a complete remission, including one patient who died 21 months after the therapy due to an infection that occurred after removal of skin cancer on his leg. The three other patients remained alive at the time of this analysis with no evidence of leukemia at 28, 52, and 53 months.

Four patients had a partial response to the therapy, with responses lasting an average of seven months. During follow-up, two of these patients died of disease progression -- one at 10 and one at 27 months after receiving CTL019.

RELATED: Dasatinib-induced Pulmonary Hypertension in Patients With Leukemia

Another study participant died after suffering a pulmonary embolism six months after treatment. The fourth patient had disease progression 13 months after therapy, but remained alive on other therapies at 36 months after the study treatment. Six patients didn't respond to the therapy, and their cancer progressed within one to nine months.

"All responding patients developed B cell aplasia and experienced cytokine release syndrome, coincident with T cell proliferation," the authors write. "Minimal residual disease was not detectable in patients who achieved complete remission, suggesting that disease eradication may be possible in some patients with advanced CLL."

The study was supported in part by a grant from Novartis, which is developing CTL019.

Reference

  1. Porter DL, Hwang W, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 2015. DOI: 10.1126/scitranslmed.aac5415.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters